Patents Examined by Stephanie Zitomer
-
Patent number: 7094535Abstract: Methods are described for the isolation of nucleic acid ligands to integrins using the SELEX process. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the present invention are useful as therapeutic and diagnostic agents.Type: GrantFiled: December 18, 2001Date of Patent: August 22, 2006Assignee: Gilead Sciences, Inc.Inventors: Judy Ruckman, Larry Gold, Andrew Stephens, Nebojsa Janjic
-
Patent number: 6867289Abstract: This invention generally relates the generation of aptamers and to the use of aptamers as diagnostic and therapeutic agents. More particularly, the present invention relates to methods using combinatorial chemistry to prepare aptamers having controlled thiophosphate replacement in the phosphate backbone for improved binding efficiencies to a target and to RNA and/or DNA products having novel nucleotide sequences and enhanced target binding efficacies.Type: GrantFiled: October 25, 1999Date of Patent: March 15, 2005Assignee: Board of Regents, The University of Texas SystemsInventors: David G. Gorenstein, Bruce A. Luxon, Norbert Herzog, Judy Aronson
-
Patent number: 6720410Abstract: The invention relates to novel nucleic acid fragments encoding polypeptides which are capable of mediating contact between enamel and cell surface. The invention also relates to expression vectors containing the nucleic acid fragments according to the invention for production of the protein, organisms containing said expression vector, methods for producing the polypeptide, compositions comprising the polypeptides, antibodies or antibody fragments recognizing the polypeptides, and methods for treating various hard tissue diseases or disorders.Type: GrantFiled: September 13, 2001Date of Patent: April 13, 2004Assignee: Biora ABInventors: Radim Cerny, Ivan Slaby, Lars Hammarström, Tilmann Wurtz, Cheng Dan Fong
-
Patent number: 6720166Abstract: Hepatitis GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to HGBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HGBV nucleic acid or amino acid sequences.Type: GrantFiled: June 5, 1995Date of Patent: April 13, 2004Assignee: Abbott LaboratoriesInventors: John N. Simons, Tami J. Pilot-Matias, George J. Dawson, George G. Schlauder, Suresh M. Desai, Thomas P. Leary, Anthony Scott Muerhoff, James Carl Erker, Sheri L. Buijk, Isa K. Mushahwar
-
Patent number: 6716583Abstract: The present invention includes methods for the identification and production of improved nucleic acid ligands based on the SELEX process. Also included are nucleic acid ligands to the HIV-RT protein identified according to the methods described therein.Type: GrantFiled: January 7, 2002Date of Patent: April 6, 2004Assignee: Gilead Sciences, Inc.Inventors: Larry Gold, Craig Tuerk
-
Patent number: 6706482Abstract: The invention provides method for producing nucleic acid ligands that generate a signal, or cause a decrease in the level of a signal, in the presence of a target molecule or an environmental stimulus. The methods of the instant invention are collectively termed Conditional SELEX. The nucleic acid ligands of the instant invention are useful in any application where it is desirable to measure the concentration of a target molecule or detect and quantitate an environmental stimulus.Type: GrantFiled: December 27, 2002Date of Patent: March 16, 2004Assignee: Somalogic, Inc.Inventors: Jonathan Drew Smith, Larry Gold
-
Patent number: 6689561Abstract: A gene that encodes an inhibitor of CDK4 has been discovered and its genomic nucleotide sequence has been identified. Susceptibility to certain cancers has been shown to be causatively related to the deletion of, or polymorphisms in, the CDK4I gene. The invention is therefore directed to the gene (CDK4I), the inhibitor protein, as well as therapeutic and diagnostic methods which utilize both the CDK4I gene and the CDK4I protein.Type: GrantFiled: April 14, 1994Date of Patent: February 10, 2004Assignee: The Regents of the University of CaliforniaInventors: Dennis A. Carson, Tsutomu Nobori
-
Patent number: 6680377Abstract: The invention relates to compositions, systems, and methods for simultaneously detecting the presence and quantity of one or more different compounds in a sample using aptamer beacons. Aptamer beacons are oligonucleotides that have a binding region that can bind to a non-nucleotide target molecule, such as a protein, a steroid, or an inorganic molecule. New aptamer beacons having binding regions configured to bind to different target molecules can be used in solution-based and solid, array-based systems. The aptamer beacons can be attached to solid supports, e.g., at different predetermined points in two-dimensional arrays. The invention includes devices, methods, and computer software for carrying out the methods.Type: GrantFiled: May 12, 2000Date of Patent: January 20, 2004Assignee: Brandeis UniversityInventors: Martin Stanton, Pieter Wensink, Alexander Stewart
-
Patent number: 6630306Abstract: Polynucleotides having allosteric properties that modify a function or configuration of the polynucleotide with a chemical effector and/or physical signal are employed primarily as biosensors and/or enzymes for diagostic and catalytic purposes. In some preferred embodiments, the polynucleotides are DNA enzymes that are used in solution/suspension or attached to a solid support as biosensors to detect the presence or absence of a compound, its concentration, or physical change in a sample by observation of self-catalysis. Chemical effectors include organic compounds such as amino acids, amino acid derivatives, peptides, nucleosides, nucleotides, steroids, and mixtures of these with each other and with metal ions, cellular metabolites or blood components obtained from biological samples, steroids, pharmaceuticals, pesticides, herbicides, food toxins, and the like. Physical signals include radiation, temperature changes, and combinations thereof.Type: GrantFiled: May 4, 2001Date of Patent: October 7, 2003Assignee: Yale UniversityInventor: Ronald R. Breaker
-
Patent number: 6630334Abstract: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the kinase peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the kinase peptides, and methods of identifying modulators of the kinase peptides.Type: GrantFiled: January 2, 2001Date of Patent: October 7, 2003Assignee: Applera CorporationInventors: Karl Guegler, Marion Webster, Valentina Di Francesco, Ellen M. Beasley
-
Patent number: 6613516Abstract: The presently claimed invention provides methods, compositions, and apparatus for studying nucleic acids. Specifically, the present invention provides a novel enrichment and labeling strategy for ribonucleic acids. In one embodiment, the invention provides enriching for a population of interest in a complex population by diminishing the presence of a target sequence. In a further embodiment, the invention can be used to reproducibly label and detect extremely small amounts of nucleic acids.Type: GrantFiled: October 11, 2000Date of Patent: September 2, 2003Assignee: Affymetrix, Inc.Inventors: Fred C. Christians, Duc Do, Thomas Gingeras, Kevin Gunderson, Charles G. Miyada, Carsten Rosenow, Kai Wu, Qing Yang
-
Patent number: 6613526Abstract: This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cells ghosts, endothelia of the blood brain and CSF-blood barriers, glioblastomas, and lymphomas are described.Type: GrantFiled: February 14, 2002Date of Patent: September 2, 2003Assignee: Gilead Sciences, Inc.Inventors: Joseph S. Heilig, Larry Gold
-
Patent number: 6610483Abstract: The present invention provides a method for the identification of a pattern of changes in cellular responses induced by the selective inhibition of a signaling molecule, by determining the specific effects of a selective inhibitor on a mutant form of a signaling molecule on cellular responses. The pattern of alterations in cellular responses resulting from the inhibition by a selective mutant inhibitor of the mutant signaling molecule are characteristic of the cellular response alterations that a specific inhibitor of the wild-type signaling molecule will produce. After determining the pattern of cellular responses of the mutant cells with the mutant molecule, compounds may be identified capable of inhibiting the wild-type molecule by producing a pattern of cellular responses in wild-type cells matching or having similarity to that of the inhibition of the mutant molecule.Type: GrantFiled: July 20, 2000Date of Patent: August 26, 2003Assignee: Princeton UniversityInventors: Kevan M. Shokat, Anthony Bishop
-
Patent number: 6602695Abstract: This invention provides a DNA polymerase that is a mutant form of a naturally occurring DNA polymerase, of which one or more amino acids in the active site are mutated. The DNA polymerase mutant of this invention is characterized by altered fidelity or altered enzymatic activity in comparison with the naturally occurring DNA polymerase. For example, the DNA polymerase mutant provides increased enzymatic activity, altered dNTP/rNTP specificity, or enhanced fidelity. In one aspect of the invention, the naturally occurring DNA polymerase comprises an amino acid sequence motif: AspTyrSerGlnIleGluLeuArg in the active site. In another aspect of the invention, the naturally occurring DNA polymerase comprises an amino acid sequence motif: LeuLeuValAlaLeuAspTyrSerGlnIleGluLeuArg in the active site.Type: GrantFiled: October 16, 2001Date of Patent: August 5, 2003Assignee: University of WashingtonInventors: Premal H. Patel, Lawrence A. Loeb
-
Patent number: 6600031Abstract: A synthetic strategy for the creation of large scale chemical diversity. Solid-phase chemistry, photolabile protecting groups, and photolithography are used to achieve light-directed spatially-addressable parallel chemical synthesis. Binary masking techniques are utilized in one embodiment. A reactor system, photoremovable protective groups, and improved data collection and handling techniques are also disclosed. A technique for screening linker molecules is also provided.Type: GrantFiled: April 21, 1998Date of Patent: July 29, 2003Assignee: Affymetrix, Inc.Inventors: Stephen P. A. Fodor, Lubert Stryer, J. Leighton Read, Michael C. Pirrung
-
Patent number: 6596491Abstract: Methods are described for the identification and preparation of nucleic acid ligands to tenascin-C. Included in the invention are specific RNA ligands to tenascin-C identified by the SELEX method. Further included in the invention are methods for detecting the presence of a disease condition in a biological tissue in which tenascin-C is expressed.Type: GrantFiled: May 14, 2001Date of Patent: July 22, 2003Assignee: Gilead Sciences, Inc.Inventors: Brian Hicke, Stephen Warren, David Parma, Larry Gold
-
Patent number: 6589742Abstract: A method for amplifying nucleic acids is provided wherein detection of amplified species is enhanced by the use of asymmetric amplification. Such amplification is made asymmetric by using divergent ratios of amplification primers or by using non-extending and/or non-cleavable amplification primers. Detection of the amplicons is improved because maintenance of single stranded species of amplicons during amplification facilitates their direct capture by immobilized probes without having to include denaturing steps.Type: GrantFiled: September 17, 2001Date of Patent: July 8, 2003Assignee: Nanogen, Inc.Inventors: Carl F. Edman, Michael I. Nerenberg, Lorelei P. Westin, John J. Carrino
-
Patent number: 6586182Abstract: Methods are provided for the evolution of proteins of industrial and pharmaceutical interest, including methods for effecting recombination and selection. Compositions produced by these methods are also disclosed.Type: GrantFiled: October 20, 2000Date of Patent: July 1, 2003Assignee: Maxygen, Inc.Inventors: Phillip A. Patten, Willem P. C. Stemmer
-
Patent number: 6582904Abstract: A method for the quantification of tumor cells in a body fluid is disclosed and entails first carrying out a reaction with the sample to be investigated, in which the RNA component of telomerase is specifically amplified, and then the amount of amplified nucleic acid is determined quantitatively, as are test kits suitable therefor.Type: GrantFiled: May 14, 1998Date of Patent: June 24, 2003Inventor: Michael W. Dahm
-
Patent number: 6582918Abstract: This invention discloses a method for preparing a complex comprised of a PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a PDGF Nucleic Acid Ligand by SELEX methodology and associating the PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more PDGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a PDGF Nucleic Acid Ligand or Complex and methods for making the same.Type: GrantFiled: May 8, 2001Date of Patent: June 24, 2003Assignee: Gilead Sciences, Inc.Inventors: Nebojsa Janjic, Larry Gold